Nov
DEC
Jan
21
2014
2015
2016
1 captures
21 Dec 15 - 21 Dec 15
Close
Help
Skip to main content
Access brought to you by:
LOCKSS
Login
Search for this keyword
Advanced Search
Main menu
HOME
BROWSE BY CONFERENCE
BROWSE BY DISCIPLINE
-- All Disciplines --
Anesthesiology
Cardiology & Cardiovascular Medicine
Dentistry
Dermatology
Endocrinology, Diabetes & Metabolism
Emergency Medicine & Critical Care
Hematology
Hepatology
Infectious Diseases
Nephrology
Neurology
Nutrition
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopaedics & Sports Medicine
Psychiatry & Psychology
Pulmonary & Respiratory Medicine
Radiology
Rheumatology
Veterinary Medicine
ABOUT
About Us
International Medical Advisory Board
Reprints
Librarian resources
Contact us
Help
Demyelinating Diseases
Postrelapse MS Treatment with Alemtuzumab Better than SC IFN-β-1a
Relapsing-Remitting Multiple Sclerosis Effectively Treated with Peginterferon Beta-1
Results of DECIDE: DAC HYP Superior to IFN-β-1a for RRMS
Fampridine Prolonged Release Improves Walking Ability and Balance in Patients with Multiple Sclerosis
HspB5 Improves MRI Lesions and Clinical Relapse in RRMS
Controversies in Multiple Sclerosis Therapy
PR—Fampridine Improves Mobility in Patients with MS
Treatment with Alemtuzumab Leads to Durable Benefits in Patients with Multiple Sclerosis
Improvement in UI with OnabotulinumtoxinA Maintained over 4 Years in Patients with MS
Potential Genetic Locus Associated with MS Identified in African Americans
Pages
Next
1
2
3